Unraveling the dual role of METTL3-mediated m6A RNA modification in bladder cancer: mechanisms, therapeutic vulnerabilities, and clinical implications
Bladder cancer (BC) remains challenging due to its recurrence and metastasis, with METTL3-mediated m6 A RNA modification emerging as a key oncogenic driver. This review synthesizes METTL3’s roles in BC progression, including tumor initiation, metastasis, stemness, and therapy resistance. We detail i...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Cancer Biology & Therapy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/15384047.2025.2545057 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Bladder cancer (BC) remains challenging due to its recurrence and metastasis, with METTL3-mediated m6 A RNA modification emerging as a key oncogenic driver. This review synthesizes METTL3’s roles in BC progression, including tumor initiation, metastasis, stemness, and therapy resistance. We detail its regulation of critical pathways (e.g. HIF1A/IGF2BP3/BIRC5, AFF4/NF-κB/c-MYC) and dual functions in RNA stability and epigenetic crosstalk with DNA methylation. METTL3 promotes chemoresistance (e.g. circ0008399/WTAP/TNFAIP3) and immune evasion (PD-L1 stabilization), while its overexpression correlates with poor prognosis and cisplatin resistance. By integrating METTL3’s interactions with m6 A readers (YTHDF1/2, IGF2BP3) and erasers (ALKBH5), we propose targeting METTL3 as a strategy to enhance chemotherapy and immunotherapy efficacy. This work underscores METTL3’s potential as a diagnostic biomarker and therapeutic target, advancing precision oncology in BC. |
|---|---|
| ISSN: | 1538-4047 1555-8576 |